cu64 trastuzumab
mAbexperimentalImaging agent
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2007 (NCT00605397)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 64-copper
Oral
No
Parenteral
No
Topical
No
Also known as
- cu64-dota-trastuzumab
- cu64 trastuzumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02827877 | N/A | Jul 1, 2016 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT02226276 | N/A | Jan 7, 2015 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT01939275 | N/A | Sep 25, 2014 | City of Hope National Medical Center |
| NCT01093612 | N/A | Mar 1, 2011 | City of Hope National Medical Center |
| NCT00605397 | Phase 1 | Jan 1, 2007 | Cornell University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 4 | 4 | 1 | 2011 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2015 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2007 |
3 organizations
Page 1 / 1